Association of Cyclosporine Dose with Early Onset Hypertension in Allogeneic Hematopoietic Cell Transplant Patients: A Cohort Study
Yves Soltermann, Jérémie Héritier, Helen Baldomero, Jakob R. Passweg, Martina Kleber · 2026
Read Association of Cyclosporine Dose with Early Onset Hypertension in Allogeneic Hematopoietic Cell Transplant Patients: A Cohort Study by Yves Soltermann, Jérémie Héritier, Helen Baldomero, Jakob R. Passweg, Martina Kleber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13163851.txt.
Description
Yves Soltermann and four co-authors ask whether a bigger starting dose of a transplant drug brings more high blood pressure, in a 2026 study. The drug, cyclosporine, guards stem cell transplant patients against attack by the donor cells. A higher first dose cuts that risk, but the drug is known to raise blood pressure, a real worry early after transplant.
The team followed 367 patients at one center who had no prior high blood pressure. Two thirds in fact developed it early on, yet the higher dose group showed no extra risk. Age, obesity, and a past transplant of one's own cells did raise the risk. The authors say the result supports the safety of the higher starting dose.
Catalog record
| CREATOR | Yves Soltermann, Jérémie Héritier, Helen Baldomero, Jakob R. Passweg, Martina Kleber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |